Experimental eczema drug trial halted before results

NCT ID NCT06119529

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 35 times

Summary

This early-phase study aimed to test the safety of a new drug called LY3872386 in healthy volunteers and people with atopic dermatitis (eczema). The trial was terminated early, so no meaningful data on safety or how the body processes the drug were collected. Only 18 participants were planned, making this a very preliminary investigation.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CenExel ACT

    Anaheim, California, 92801, United States

  • Fortrea Clinical Research Unit

    Daytona Beach, Florida, 32117, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

LY3872386

What could go wrong

This was a very early, small study that was terminated, so no results are available. It is unclear if the drug is safe or effective.

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.